AbbVie has pointed to a very strong launch trajectory for Elahere, with sales rocketing to $480 million last year, almost ...

Measles cases in the European region doubled to 127,350 in 2024, reaching the highest level in nearly three decades and ...

One of the key open questions in cell and gene therapy is which will win out: autologous cell therapies, where the patient’s ...

According to Prof Phil Banfield, chair of the BMA council, it had become clear that the centre "no longer has a grip on the ...

The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...

Jane Chung, president and chief operating officer at Sutro, is replacing Bill Newell as chief executive as the company starts ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...

At Veeva Commercial Summit late 2024, web editor Nicole Raleigh spoke with Veeva Systems’ president of Europe, Chris Moore, for a discursive dive into the life sciences during the year.

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...

Clinical trials are constantly pushing the boundaries of innovation. Over the past few years, there’s been an explosion of advancements, such as the widespread use of biomarkers in precision ...

President Donald Trump has withdrawn his nomination of Dave Weldon to lead the CDC, just hours before he was due to appear in ...

The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...